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Abstract—The understanding of the type of inhibitory in-
teraction plays an important role in drug design. Therefore,
researchers are interested to know whether a drug has competitive
or non-competitive interaction to particular protein targets.
Method: to analyze the interaction types we propose factorization
method Macau which allows us to combine different measurement
types into a single tensor together with proteins and compounds.
The compounds are characterized by high dimensional 2D ECFP
fingerprints. The novelty of the proposed method is that using
a specially designed noise injection MCMC sampler it can
incorporate high dimensional side information, i.e., millions of
unique 2D ECFP compound features, even for large scale datasets
of millions of compounds. Without the side information, in this
case, the tensor factorization would be practically futile.
Results: using public IC50 and Ki data from ChEMBL we
trained a model from where we can identify the latent subspace
separating the two measurement types (IC50 and Ki). The results
suggest the proposed method can detect the competitive inhibitory
activity between compounds and proteins.
Keywords—tensor factorization, side information, high scale
machine learning, MCMC, drug-protein binding, IC50, Ki.
I. INTRODUCTION
In pharmaceutical research two properties, affinity and po-
tency, are commonly measured in-vitro. Affinity measures the
concentration of the tested substance needed to occupy a given
portion of the available binding sites, usually measured by the
inhibitory constant Ki which have an intuitive meaning: the
free substance concentration in chemical equilibrium where the
half of the available binding sites are occupied. This value is
independent of the concentration of the protein.
Potency measures the concentration of the substance to
reach a given level of effect. In case of inhibitory compounds
most often measured by relative IC50. Relative IC50 is the
concentration of the substance, where the halfway activity
between the baseline and the maximal inhibition is reached.
Assuming Michaelis-Menten kinetics, it is easy to see that if
there is no interaction between the binding processes, IC50 =
Ki even in the case of partial inhibitors. This can be true
when there is only one substance binding to the binding site
of interest, so the binding site of the inhibitor is allosteric to
the binding site where the effect is measured, illustrated on the
left panel of Fig. 1. If, however, there is competition between
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Fig. 1. Two main types of inhibition.
the inhibitor and an endogenous ligand (illustrated on the right
panel of Fig. 1), IC50 will be dependent of the concentrations
of the endogenous ligand and its interaction with the protein.
The relation in the logarithmic scale has the form [1]:
pKi = pIC50 + C ([S],Km) , (1)
where pKi = − log10Ki, pIC50 = − log10 IC50, [S] is
the concentration of the endogenous substrate S, Km is the
Michaelis constant of the enzyme with respect to S, and
C([S],Km) is an additive constant with respect to pIC50,
depends on the experimental conditions. This form holds in
the case of uncompetitive inhibition as well.
We want to build a Bayesian model for the Eq. 1 by jointly
modeling both pIC50 and pKi, using data from different
proteins and compounds. The joint model can capture whether
the deviation term C([S],Km) is zero (corresponding to non-
competitive interaction) or non-zero (corresponding to com-
petitive interaction). Therefore, we propose a model that uses
low-rank approximation of the 3-way tensor Y where Yijk is
the measured inhibition of protein j with compound i for the
given inhibition measure k (either pKi or pIC50):
Yijk ≈ 1>(ci ◦ pj ◦ tk), (2)
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Fig. 2. Tensor factorization for pIC50 and pKi modeling with side
information on compounds.
where ci,pj , tk ∈ RD are the respective D-dimensional latent
vectors and 1 is a vector of ones. The tensor Y is thin as there
are only two measure types.
It is a natural property of tensor factorization that additive
and uncorrelated effects will occupy different latent dimen-
sions. This is the case for the Eq. 1 and, thus, we expect
few specific latent dimensions to capture the difference term
C([S],Km).
A. Side Information
However, one important issue with the factorization (2)
is that the tensor Y is very sparsely observed with less
than 1% measured values. To solve this issue we propose
to use 2D ECFP chemical features as a side information for
compounds while performing the factorization (2). The ECFP
features represent the substructures of the compound, which
are strongly related to its interaction properties. The proposed
model learns a link matrix βc ∈ RD×Fc to predict latent
vectors ci from features xi ∈ RFc , where Fc is the number
of side information features. As will become evident from the
experiments the incorporation of ECFP features gives a very
strong improvement to the accuracy of the model. The general
setup for the model is depicted in Fig. 2.
To sample from this model we develop a Bayesian factor-
ization approach Macau based on Gibbs sampling. The novelty
of Macau is that in can scale well with respect to the number
of features Fc. This is crucial for the current application as
the dimension of the ECFP features Fc is more than 100,000.
In contrast, the recent sampling-based Bayesian factorization
methods Bayesian Matrix Factorization with Side Information
(BMFSI) [2] and Bayesian Canonical PARAFAC with Features
and Networks (BCPFN) [3] require explicitly computing the
covariance matrix of size Fc × Fc for linking the features
to the factorization. Additionally, to sample the link vector
Cholesky decomposition is necessary, taking at least O(Fc3),
which makes these methods intractable for high-dimensional
feature spaces.
Instead, Macau samples the link matrix βc without explicitly
computing its covariance matrix by using a specially designed
noise injection sampler that we describe in the Section III-A.
II. STATISTICAL MODEL
In this section we first describe the statistical model, and
explain related work in tensor factorization literature.
A. General Setup
The observation noise is assumed to be Gaussian, as was
proposed in Bayesian Probabilistic Matrix Factorization [4],
p(Y|c,p, t, α) =
∏
(i,j,k)∈I
N (Yijk|1>(ci ◦pj ◦tk), α−1), (3)
where N is the normal distribution, I is the set of tensor cells
whose value has been observed and α is the noise precision.
Next we place a common multivariate Gaussian prior on the
latent vectors of compounds
p(ci|Λc, µc,xi, βc) = N (ci|µc + βcxi,Λc), (4)
where µc ∈ RD and Λc ∈ RD×D are the shared intercept
vector and precision matrix for all compounds. The term βcxi
allows the prior mean of ci to depend on the compound
features xi and, therefore, have informed predictions also
for compounds with very few or no measurements. We use
analogous prior also for the latent vectors of proteins pj and
measurements tk. For proteins we use basic sequence based
features, described in more detail Section IV-A. Without the
βcxi in the prior (4) our model is equivalent to Bayesian Prob-
abilistic Tensor Factorization [5]. Originally, the adjustment of
the prior mean was first proposed by Agarwal et al. [6] for non-
Bayesian models. Recently, this side information adjustment
was used for sparse tensor factorization in BCPFN [3].
B. Scale Invariant Prior on the Link Matrix
The standard approach in the previous works, for example
used by Rai et al. [3], has been to add a zero-mean Gaussian
prior on βc, i.e., vec(βc) ∼ N (0, λβcI), where I is the identity
matrix and λβc ∈ R+ is precision value.
Instead, we propose a prior whose scale depends on Λc,
making the strength of the prior invariant to the scale of the
latent variables:
p(βc|Λc, λβc) = N (vec(βc)|0,Λc ⊗ λβcIFc), (5)
where ⊗ is Kroenecker product. The prior has advantage of
being well suited for sampling, as we show in the next section.
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III. GIBBS SAMPLER
We develop a block Gibbs sampler for the model. For most
variables the samplers are straight-forward, and due to space
restrictions are left to an extended version of the paper [7].
The crucial question is how to sample βc whose dimensions
in our experiments are 30 × 105,672 but can be even larger
for bigger datasets.
The main idea of our noise injection sampler is that we will
construct a specific linear system whose solution corresponds
to a sample from the conditional probability of βc. For large
feature dimension Fc the linear system of size Fc × Fc will
be solved without explicitly computing it by using iterative
solvers, which only require (sparse) matrix multiplication
operations.
A. Noise Injection Sampler for the Link Matrix
The conditional posterior of βc, used for Gibbs sampler,
combines (4) and (5). Due to scale invariance of (5) we get
p(βc) ∝ exp(−1
2
tr[((U−Xβ>c )>(U−Xβ>c )+λβcβ>c βc)Λc])
(6)
where for conciseness we have dropped the conditional terms
after βc and use shorthands U = [c1−µc, . . . , cNc−µc]> and
X = [x1, . . . ,xNc ]
>. From this we can derive the Gaussian
mean and precision of βc as
p(βc) = N (K−1X>U,Λ−1c ⊗K−1), (7)
where K = X>X + λβcI. Naively sampling from Gaussian
(7) would cost O(Fc3D3) time. However, due to the special
structure of the distribution (7) we can generate its sample by
solving following Fc × Fc linear systems
Kβ˜c = X
>(U+E1) +
√
λβcE2 (8)
with respect to β˜c, where E1 and E2 are noise matrices where
each row is drawn from N (0,Λ−1c ). We call (8) the noise
injection sampler as it adds noise to the right-hand sides
of the linear systems. The correctness of the noise injection
sampler is proved in extended version, see [7]. The RHS of
the system (8) has dimension Fc × D, i.e., there are total
of D systems, which can be solved independently, using
embarrassingly parallel approach.
We propose to use conjugate gradient to solve (8). In its
iterations conjugate gradient only requires multiplication of K
with a dense vector. This allows us to handle side information
with millions of sparse features X because the multiplication
Kv can be expressed as two sparse-matrix-vector-products and
an addition:
Kv = X>(Xv) + λβcv. (9)
In an analogous way, we introduced side information for the
proteins.
The software implementation of Macau is freely available1.
1https://github.com/jaak-s/BayesianDataFusion.jl
TABLE I. EFFECT OF SIDE INFORMATION ON RMSE (ON TEST SET)
Method RMSE (Stdev)
Macau with SI 0.5970 (0.0054)
Macau without SI 0.8703 (0.0085)
IV. EXPERIMENTS
A. Data
The inhibitory activities were obtained from ChEMBL [8]
version 19. The dimensions of the tensor Y are Nc = 15,073,
Np = 346 and Nt = 2, with 59,280 observed values for pIC50,
and 5,121 for pKi.
We generate ECFP features of radius 3 for the compounds
by using RDKit software [9]. These features are sparse and
high dimensional with Fc = 105,672.
To have a basic description for proteins we use protein
features based on information extracted directly from position-
specific frequency matrices (PSFM). Accordingly, we link each
protein to a 20 dimensional feature vector created by summing
up each column in the PSFM profile as done in [10].
B. Results
In this subsection we present empirical results on ChEMBL
dataset. In all experiments we used Macau with D = 30 latent
dimensions.
1) Effect of side information: We compare Macau with and
without side information in a hold-out validation setting, which
we repeat 10 times. On each run, we randomly select 20% of
the pIC50 measurements as the test set. The mean and standard
deviation of the RMSEs show that the side information plays a
crucial role to have accurate predictions for pIC50, see Table I.
2) Latent dimensions capturing the difference term: We
compare the latent vectors of pIC50 and pKi, i.e. t1 and t2.
Figure 3 depicts the normalized2 values of latent dimensions in
the two vectors t1 and t2, from a single posterior sample. As
we can see from the figure, in three latent dimensions, colored
green, red and yellow, the values corresponding to pIC50 and
pKi differ significantly. The difference term C([S],Km) in (1)
is captured by these three latent dimensions, as expected.
As can be seen from the animation3, the behavior of these 3
latent dimensions through the posterior samples is stable and
is qualitatively identical to Figure 3. Next we investigate the
predictive properties of these 3 latent dimensions.
3) Prediction of dominant interaction types for proteins: We
used the identified three latent dimensions from the previous
section to rank the proteins according to their predicted binding
behavior. Let m be an indicator vector where d-th element is
1 exactly if the d-th latent vector is one of the 3 selected. We
computed the absolute difference between the predicted pIC50
and pKi values
Cij = |m>(ci ◦ pj ◦ (t2 − t1))|,
2For normalization both t1,d and t2,d are multiplied by Euclidean norms
of compounds and proteins ‖c(d)‖‖p(d)‖.
3Animation is available at https://youtu.be/RSrVfUwYYw4
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Fig. 3. Normalized latent dimensions of measurement types pIC50 and pKi.
where t2 is the latent vector for pKi, and t1 is for pIC50.
Since our model is Bayesian, we average Cij over all posterior
samples, as in the previous sections, and denote it by Cˆij .
Next, we computed the 0.95 quantile of Cˆij for each protein
j, which is a robust estimate for the maximal difference term
C([S],Km) in (1) for protein j. We order all the proteins
according to this quantile, and extracted the top and the bottom
10 of this list. We expect that the top 10 proteins, shown
in Table II, to have strong competitive interactions. As can
be seen from the table, all 10 are enzymes, which makes
it probable that our expectation is correct, because enzymes
usually have some strongly competitive inhibitors. Secondly,
we expect the bottom 10 proteins, shown in Table III, to
be generally non-competitive, which also seems to be the
case because there are 7 receptors and 2 ion channels. To
understand what pIC50 measures for receptors, one has to
know how the assays are designed. In the assays of receptors
and ion channels, the inhibitory response is measured on the
intracellular end of the signal, which is non-competitive, even
though on the extracellular site there could be competition for
the site. An alternative explanation is that the proposed model
detects deviations from Michaelis-Menten kinetics.
As the tables were constructed only using the selected 3
latent dimensions, it shows that the tensor factorization has
the ability to extract the differential term C([S],Km) into few
latent dimensions.
4) Prediction of compound-protein interaction types: In this
experiment we try a challenging task to predict if a compound-
protein pair have competitive interaction (pKi 6= pIC50). We
select 30 compound-protein pairs to the test set, for which
both pIC50 and pKi are available. 10 pairs are randomly
selected from the top 100 pairs having the highest positive
difference pKi − pIC50, next 10 from the 100 pairs having
the highest negative difference, and the final 10 from the 100
pairs having the least absolute difference. From the Macau
predictions (using all latent dimensions) we compute the
difference pKi − pIC50 for the pairs in the test set.
Macau is able to capture signal from the data as the
mean predicted absolute difference, |pKi − pIC50|, for the
TABLE II. TOP10 PROTEINS WITH PREDICTED COMPETITIVE
INTERACTION
ChEMBL ID Protein name
CHEMBL284 Dipeptidyl peptidase IV
CHEMBL325 Histone deacetylase 1
CHEMBL260 MAP kinase p38 alpha
CHEMBL1865 Histone deacetylase 6
CHEMBL1937 Histone deacetylase 2
CHEMBL289 Cytochrome P450 2D6
CHEMBL4005 PI3-kinase p110-alpha subunit
CHEMBL1978 Cytochrome P450 19A1
CHEMBL2581 Cathepsin D
CHEMBL4793 Dipeptidyl peptidase IX
TABLE III. TOP10 PROTEINS WITH PREDICTED NON-COMPETITIVE
INTERACTION
ChEMBL ID Protein name
CHEMBL240 HERG
CHEMBL3772 Metabotropic glutamate receptor 1
CHEMBL5145 Serine/threonine-protein kinase B-raf
CHEMBL3663 Growth factor receptor-bound protein 2
CHEMBL4641 Voltage-gated T-type calcium channel alpha-1G subunit
CHEMBL3230 Sphingosine 1-phosphate receptor Edg-6
CHEMBL2001 Purinergic receptor P2Y12
CHEMBL1785 Endothelin receptor ET-B
CHEMBL287 Sigma opioid receptor
CHEMBL3227 Metabotropic glutamate receptor 5
competitive pairs is 0.671 and for the non-competitive pairs
is 0.234. The difference is statistically significant at 1% level
(with t-test p-value of 0.0047).
V. CONCLUSION
In this paper we presented a novel scalable Bayesian tensor
factorization method with side information in a novel applica-
tion for the prediction of drug-protein interaction types.
We showed that the method can capture the difference
between binding affinity and potency from highly sparse data.
With this model we can predict the dominant interactions
types of the proteins and the competitiveness of the inhibition
between compound-protein pairs.
The future work is to execute this factorization model on
large scale industrial dataset and make it directly usable for
drug design process. We also plan to extend the model for
slow tight-binding inhibitors.
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